β-glucan ameliorates methotrexate-induced oxidative organ injury via its antioxidant and immunomodulatory effects

European Journal of Pharmacology

Volumn 542, Issue 1-3, 2006, Pages 170-178

  Şener, Göksel ^a   Ekşioǧlu Demiralp, Emel ^a   Çetiner, Mustafa ^a   Ercan, Feriha ^a   Yeǧen, Berrak Ç ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

glucan; Apoptosis; Glutathione; Lipid peroxidation; Myeloperoxidase activity; TNF

Indexed keywords

ANTIOXIDANT; BETA GLUCAN; COLLAGEN; GLUTATHIONE; MALONALDEHYDE; METHOTREXATE; MYELOPEROXIDASE; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DECAPITATION; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HISTOLOGY; ILEUM; IMMUNOMODULATION; IMMUNOREGULATION; KIDNEY; LEUKOCYTE; LIVER; MALE; NEUTROPHIL; NONHUMAN; ORGAN INJURY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION; RAT; SINGLE DRUG DOSE; TISSUE INJURY;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; BETA-GLUCANS; CELL SURVIVAL; COLLAGEN; FEMALE; FOLIC ACID ANTAGONISTS; GLUTATHIONE; ILEUM; IMMUNOLOGIC FACTORS; KIDNEY; LIVER; LYMPHOCYTES; MALE; MALONDIALDEHYDE; METHOTREXATE; NEUTROPHILS; OXIDATIVE STRESS; PEROXIDASE; RATS; RATS, WISTAR; RESPIRATORY BURST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746001411     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.02.056     Document Type: Article

References (45)

1. Babiak R.M.V., Campello A.P., Carnieri E.G.S., and Oliveira M.B.M. Methotrexate: pentose cycle and oxidative stress. Cell Biochem. Funct. 16 (1998) 283-293
2. Babincova M., Bacova Z., Machova E., and Kogan G. Antioxidant properties of carboxymethyl glucan: comparative analysis. J. Med. Food 5 (2002) 79-83
3. Beuge J.A., and Aust S.D. Microsomal lipid peroxidation. Methods Enzymol. 53 (1978) 302
4. Beutler E. Glutathione in red blood cell metabolism: A manual of biochemical methods vol. 112 (1975), Grune and Stratton, New York
5. Browder I.W., Williams D.L., Kitahama A., and Di Luzio N.R. Modification of post-operative C. albicans sepsis by glucan immunostimulation. Int. J. Immunopharmacol. 6 (1984) 19-26
6. Browder W., Williams D., Pretus H., Olivero G., Enrichens F., Mao P., and Franchello A. Beneficial effect of enhanced macrophage function in the trauma patient. Ann. Surg. 211 (1990) 605-612
7. Brown G.D., and Gordon S. Fungal β-glucans and mammalian immunity. Immunity 19 (2003) 311-315
8. Brown G.D., Herre J., Williams D.L., Willment J.A., Marshall A.S.J., and Gordon S. Dectin-1 mediates the biological effects of β-glucans. J. Exp. Med. 197 (2003) 1119-1124
9. Caetano N.N., Campello A.P., Carnieri E.G.S., Kluppel M.L.W., and Oliveira M.B.M. Effects of methotrexate (MTX) on NAD(P)+ dehydrogenases of HeLa cells: malic enzymes, 2-oxoglutarate and isocitrate dehydrogenases. Cell Biochem. Funct. 15 (1997) 259-264
10. Cleary J.A., Kelly G.E., and Husband A.J. The effect of molecular weight and β-1,6-linkages on priming of macrophage function in mice by (1,3)-β-D-glucan. Immunol. Cell Biol. 77 (1999) 395-403
11. Delatte S.J., Evans J., Hebra A., Adamson W., Othersen H.B., and Tagge E.P. Effectiveness of beta-glucan collagen for treatment of partial-thickness burns in children. J. Pediatr. Surg. 36 (2001) 113-118
12. Doan T., and Massarotti E. Rheumatoid arthritis: an overview of new and emerging therapies. J. Clin. Pharmacol. 45 (2005) 751-762
13. Eksioglu-Demiralp E., Direskeneli H., Kibaroǧlu A., Yavuz Ş., Ergun T., and Akoǧlu T. Neutrophil activation in Behcet's disease. Clin. Exp. Rheumatol. 19 (2001) S19-S24
14. Engstad C.S., Engstad R.E., Olsen J.O., and Osterud B. The effect of soluble β-1,3-glucan and lipopolysaccharide on cytokine production and coagulation activation in whole blood. Int. Immunopharmacol. 2 (2002) 1585-1597
15. Galivan J., Nimec Z., and Balinska M. Regulation of methotrexate polyglutamate accumulation in vitro: effects of cellular folate content. Biochem. Pharmacol. 32 (1983) 3344-3347
16. Hall P.M., Jenner M.A., and Ahern M.J. Hepatotoxicity in a rat model caused by orally administered methotrexate. Hepatology 14 (1991) 906-910
17. Hashimoto T., Ohno N., Adachi Y., and Yadomae T. Enhanced production of inducible nitric oxide synthase by β-glucans in mice. FEMS Immunol. Med. Microbiol. 19 (1997) 131-135
18. Helen S.T.E., Schiano T.D., Kuan S.F., Hanauer S.B., Conjeevaram H.S., and Baker A.L. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am. J. Gastroenterol. 95 (2000) 3150-3156
19. Hersh E.M., Wong V.G., Henderson E.S., and Freirich E.J. Hepatotoxic effects of methotrexate. Cancer 19 (1966) 600-606
20. Hillegass L.M., Griswold D.E., Brickson B., and Albrightson-Winslow C. Assessment of myeloperoxidase activity in whole rat kidney. J. Pharmacol. Methods 24 (1990) 285-295
21. Jolivet J., Cowan K.H., Curt G.A., Clendeninn N.J., and Chabner B.A. The pharmacology and clinical use of methotrexate. N. Engl. J. Med. 309 (1983) 1094-1104
22. Kamen B.A., Nylen P.A., Camitta B.M., and Bertino J.R. Methotrexate accumulation and folate depletion in cell as a possible mechanism of chronic toxicity to the drug. Br. J. Hematol. 49 (1981) 355-360
23. Kintzel P.E. Anticancer drug-induced kidney disorders. Drug Safety 24 (2001) 19-38
24. Krizkova L., Durackova Z., Sandula J., Slamenova D., Sasinkova V., Sivonova M., and Krajcovic J. Fungal beta-(1-3)-D-glucan derivatives exhibit high antioxidative and antimutagenic activity in vitro. Anticancer Res. 23 3B (2003) 2751-2756
25. Ljungman A.G., Leanderson P., and Tagesson C. (1-3)-β-D-glucan stimulates nitric oxide generation and cytokine mRNA expression in macrophages. Environ. Toxicol. Pharmacol. 5 (1998) 273-281
26. Lopez De Leon A., and Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed parraffin-embedded sections. J. Histochem. Cytochem. 33 (1985) 737-743
27. Nakagawa Y., Ohno N., and Murai T. Suppression by Candida albicans β-glucan of cytokine release from activated human monocytes and from T cells in the presence of monocytes. J. Infect. Dis. 187 (2003) 710-713
28. Neuman M.G., Cameron R.G., Haber J.A., Katz G.G., Malkiewicz I.M., and Shear N.H. Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatotoxicity. Clin. Biochem. 32 (1999) 519-536
29. Onderdonk A.B., Cisneros R.L., Hinkson P., and Ostroff G. Anti-infective effect of poly-β1-6-glucotriosyl-β1-3-glucopyranose glucan in vivo. Infect. Immun. 60 (1992) 1642-1647
30. Robinson J.P. Handbook of flow cytometry methods. Oxidative Burst (1993), Willey-Liiss Inc., New York 145-154
31. Roenigk H.H., Bergfield W.F., ST. Jacquez R., Owens F.J., and Hawk W.A. Hepatotoxicity of methotrexate in the treatment of psoriasis. Arch. Dermatol. 103 (1971) 250-261
32. Ross D. Glutathione, free radicals and chemotherapeutic agents. Pharmacol. Ther. 37 (1988) 231-249
33. Sener G., Toklu H., Ercan F., and Erkanli{dotless} G. Protective effect of beta-glucan against oxidative organ injury in a rat model of sepsis. Int. Immunopharmacol. 5 (2005) 1387-1396
34. Soltys J., and Quinn M.T. Modulation of endotoxin- and enterotoxin-induced cytokine release by in vitro treatment with β-(1,6)-branched β-(1,3)-glucan. Infect. Immun. 67 (1999) 244-252
35. Sullivan G.W., Sarembock I.J., and Linden J. The role of inflammation in vascular diseases. J. Leukoc. Biol. 67 (2000) 591-602
36. Takei H., Araki A., Watanabe H., Ichinose A., and Sendo F. Rapid killing of human neutrophils by the potent activator phorbol 12-myristate 13-acetate (PMA) accompanied by changes different from typical apoptosis or necrosis. J. Leukoc. Biol. 59 (1996) 229-240
37. Takeshita K., Watanuki S., Iida M., Saito N., Maruyama M., Sunagawa M., Habu H., and Endo M. Effect of lentinan on lymphocyte subsets of peripheral blood, lymph nodes, and tumor tissues in patients with gastric cancer. Surg. Today 23 (1993) 125-129
38. Tobias H., and Auerbach R. Hepatotoxicity of long term methotrexate therapy for psoriasis. Arch. Intern. Med. 132 (1973) 391-396
39. Toklu H.Z., Sener G., Jahovic N., Uslu B., Arbak S., and Yeǧen B.C. Beta-glucan protects against burn-induced oxidative organ damage in rats. Int. Immunopharmacol. 6 (2006) 156-169
40. Vaziri N.D. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin. Nephrol. 24 (2004) 469-473
41. Vetvicka V. β-glucans as immunomodulators. JANA 3 (2001) 31-34
42. Vetvicka V., Tereyama K., Mandeville R., Brousseau P., Kournikakis B., and Ostroff G. Piloy study: orally-administered yeast β1,3-glucan prophylactically protects against anthrax infection and cancer in mice. JANA 5 (2002) 1-5
43. Vogel W.H., Snyder R., and Schulman M.P. The inhibition of dehydrogenases by folic acid and several of its analogs. Biochem. Biophys. Res. Comm. 10 (1963) 97-101
44. Wei D., Williams D., and Browder W. Activation of AP-1 and SP1 correlates with wound growth factor gene expression in glucan-treated human fibroblasts. Int. Immunopharmacol. 2 (2002) 1163-1172
45. Williams D.L., Ha T., Li C., Kalbfleisch J.H., Laffan J.J., and Ferguson D.A. Inhibiting early activation of tissue nuclear factor-ÊÂ and nuclear factor interleukin 6 with (1-3)-β-D-glucan increases long-term survival in polymicrobial sepsis. Surgery 126 (1999) 54-65